可溶性Fas：尿毒症炎症的一种新型标志物。

Soluble Fas: a novel marker of inflammation in uremia.

作者信息

Dalboni Maria Aparecida, Sardenberg Camila, Andreoli Maria Claudia, Watanabe Renato, Canziani Maria Eugênia, Santos Bento F C dos, Liangos Orfeas, Jaber Bertrand L, Draibe Sérgio, Cendoroglo Miguel

机构信息

Division of Nephrology, Department of Medicine, Universidade Federal de São Paulo, São Paulo, SP, Brazil.

出版信息

Artif Organs. 2003 Aug;27(8):687-91. doi: 10.1046/j.1525-1594.2003.07274.x.

DOI:10.1046/j.1525-1594.2003.07274.x

PMID:12911341

Abstract

BACKGROUND

Inflammation has been associated with atherosclerotic cardiovascular disease (CVD) and anemia in patients with end-stage renal disease (ESRD). Recent studies have shown that serum levels of soluble Fas (sFas), an antiapoptotic and proinflammatory molecule, are elevated in patients with cardiac disease and patients with ESRD. We therefore sought to investigate serum levels of sFas in uremic patients and its correlation with known markers of inflammation, anemia and CVD.

METHODS

The study included 25 ESRD patients (14 on hemodialysis, 11 on CAPD), 27 patients with chronic kidney disease (CKD; creatinine clearance <50 ml/min/1.73 m2), and 14 normal control subjects. We measured serum levels of sFas, C-reactive protein (CRP), and albumin. We also investigated the association of serum sFas levels with the presence of CVD and with erythropoietin (EPO) dosage.

RESULTS

Levels of sFas were elevated in CKD and ESRD patients compared to controls. sFas levels correlated negatively with creatinine clearance. In the dialysis patients, we observed that sFas levels were higher among those with CVD. Serum levels of sFas correlated with serum levels of CRP (r=0.31; P=0.03), serum levels of albumin (r=-0.35, P=0.02), and EPO dosage (r=0.51; P=0.009).

CONCLUSION

These results suggest that sFas may be a marker of inflammation in CKD and ESRD patients.

摘要

背景

炎症与终末期肾病（ESRD）患者的动脉粥样硬化性心血管疾病（CVD）及贫血相关。近期研究表明，抗凋亡及促炎分子可溶性Fas（sFas）的血清水平在心脏病患者及ESRD患者中升高。因此，我们试图研究尿毒症患者的血清sFas水平及其与已知炎症、贫血和CVD标志物的相关性。

方法

该研究纳入了25例ESRD患者（14例接受血液透析，11例接受持续性非卧床腹膜透析）、27例慢性肾脏病（CKD；肌酐清除率<50 ml/min/1.73 m²）患者及14例正常对照者。我们检测了血清sFas、C反应蛋白（CRP）及白蛋白水平。我们还研究了血清sFas水平与CVD的存在及促红细胞生成素（EPO）剂量的相关性。

结果

与对照组相比，CKD和ESRD患者的sFas水平升高。sFas水平与肌酐清除率呈负相关。在透析患者中，我们观察到患有CVD的患者sFas水平更高。血清sFas水平与CRP血清水平（r = 0.31；P = 0.03）、白蛋白血清水平（r = -0.35，P = 0.02）及EPO剂量（r = 0.51；P = 0.009）相关。